ClinicaliQ Trial Snapshot
- Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations — Active Not Recruiting • Phase II • Gastroenterology • NCT04641442.
- MAS825 tested as treatment for rare genetic inflammatory disorders caused by NLRC4, XIAP, or CDC42 mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations. Conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations Interventions: MAS825, Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 17 participants